Product image of Meriofert® Pfs (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert® Pfs

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert® Pfs (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert® Pfs, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is prescribed to treat infertility caused by anovulation and to replace deficient gonadotropins in hypogonadotropic hypogonadism.
GNH India supplies Meriofert® Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert® Pfs is a gonadotropin used in reproductive‑endocrine disorders to restore or stimulate ovarian function.

  • Infertility due to anovulation: promotes follicular growth and induces ovulation.
  • Hypogonadotropic hypogonadism: replaces deficient FSH and LH to re‑establish normal ovarian activity.
  • Assisted reproductive technology cycles: supports controlled ovarian stimulation in IVF and ICSI protocols.

How It Works

  • The preparation contains both follicle‑stimulating hormone (FSH) and luteinising hormone (LH). After subcutaneous injection, the hormones bind to their respective receptors on ovarian granulosa and theca cells, activating intracellular signaling pathways that drive follicular maturation, estradiol synthesis, and luteal phase support, ultimately leading to ovulation.

Side Effects

Common Side Effects

  • Injection site pain or erythema: mild local reaction at the injection site.
  • Abdominal discomfort: transient bloating or mild cramping.
  • Headache: mild to moderate intensity.
  • Nausea: occasional upset stomach.
  • Breast tenderness: mild swelling or soreness.
  • Mild ovarian hyperstimulation syndrome (OHSS): mild abdominal distension.

Serious or Rare Side Effects

  • Severe OHSS: rapid weight gain, ascites, or respiratory distress.
  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Allergic reactions: rash, itching, or anaphylaxis.
  • Pulmonary edema: fluid accumulation in lungs.
  • Ectopic pregnancy: implantation outside the uterus.
  • Multiple pregnancy: gestation of twins or higher order multiples.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient history and monitor response closely.

  • Pregnancy testing: confirm the patient is not pregnant prior to starting treatment.
  • Ovarian monitoring: perform ultrasound to detect excessive follicular response.
  • Hormone levels: check baseline FSH, LH, and estradiol values.
  • Thrombotic risk: evaluate history of clotting disorders.
  • Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Meriofert® Pfs may interact with several drug classes that affect reproductive hormones or coagulation.

Major Interactions (Avoid)

  • GnRH agonists: may amplify gonadotropin response, increasing OHSS risk.
  • GnRH antagonists: may blunt the intended effect of FSH/LH.
  • Ovarian stimulation agents (e.g., clomiphene): heightened risk of excessive ovarian response.
  • Steroid hormones: can alter endogenous hormone balance.
  • Anticoagulants: increased bleeding risk at injection sites.

Moderate Interactions (Monitor Closely)

  • Thyroid hormone therapy: monitor thyroid function tests.
  • Antidiabetic agents: observe glucose fluctuations.
  • NSAIDs: may mask pain from ovarian enlargement.
  • Antidepressants: watch for mood changes.
  • Herbal supplements (e.g., phytoestrogens): possible interference with hormone activity.

Frequently Asked Questions

Meriofert® Pfs is a combination of follicle‑stimulating hormone (FSH) and luteinising hormone (LH) used to treat infertility caused by anovulation and to replace deficient gonadotropins in patients with hypogonadotropic hypogonadism, supporting ovarian follicle development and ovulation.

Both hormones bind to specific receptors on ovarian cells. FSH stimulates granulosa cells to promote follicular growth and estradiol production, while LH acts on theca cells and the mature follicle to trigger ovulation and luteal phase support, together restoring normal reproductive function.

The dose of Meriofert® Pfs is individualized. A qualified prescriber determines the amount and schedule based on the patient’s hormonal profile, response to therapy, and specific treatment goals. No fixed regimen is provided in public information.

Meriofert® Pfs is intended for use before conception to induce ovulation. It is not recommended during an established pregnancy, and safety data for breastfeeding are limited. Clinicians should evaluate risks and benefits before prescribing to women who are pregnant or nursing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Meriofert® Pfs combines both FSH and LH in a single formulation, which can simplify dosing compared with separate FSH‑only preparations. This dual action may better mimic natural ovarian stimulation, but choice of product depends on individual patient response, protocol preferences, and clinician experience.

Meriofert® Pfs should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any product that has been exposed to temperatures outside the recommended range.

The medication is supplied as a sterile injectable solution for subcutaneous injection. A healthcare professional prepares the dose using aseptic technique and administers it into the subcutaneous tissue, typically in the abdomen or thigh, following the prescriber’s instructions.

Serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain, and respiratory distress, as well as thromboembolic events, allergic reactions, pulmonary edema, ectopic pregnancy, and multiple gestations. Prompt medical attention is required if these occur.

Meriofert® Pfs is contraindicated in women who are currently pregnant, have known hypersensitivity to the product, have uncontrolled thyroid disease, active ovarian cysts, or a history of severe OHSS. Patients with uncontrolled endocrine disorders or significant cardiovascular disease should also avoid its use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT